Clinical Trial Update: Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated a single intramuscular dose of nirsevimab to prevent hospitalizations due to respiratory syncytial virus in healthy term and preter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Nirsevimab (nirsevimab)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: RSV Immunization, Healthy Volunteer | Phase 3 | Status: COMPLETED | Results posted: 2025-04-11